To quantify changes in SLC9A2 protein levels between primary tumors and liver metastases, we extracted proteins from organoids derived from three patients, revealing that SLC9A2 expression in PDOs from liver metastases was significantly lower than in primary CRC (Fig. 1P). This evidence concerns the gene SLC9A2 and colorectal carcinoma.